Overview

Innoviva, Inc. (NASDAQ: INVA) is focused on royalty management. Innoviva’s portfolio includes the respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”), ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”) and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva is also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), relating to TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

ANORO®, RELVAR®, BREO®, TRELEGY® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

Royalties Earned

Royalties Earned 2019

Press Releases

Date Title and Summary
Toggle Summary Theravance and GlaxoSmithKline Form Alliance to Develop Next-Generation Respiratory Medicines
Theravance and GlaxoSmithKline Form Alliance to Develop Next-Generation Respiratory Medicines SOUTH SAN FRANCISCO, CA and LONDON, UK Date: January 6, 2003 Theravance, Inc. and GlaxoSmithKline plc (LSE & NYSE: GSK) announced today that they have formed an alliance to develop and commercialize novel
Toggle Summary Theravance Announces Promising Results From Multiple Research And Clinical Studies With the Investigational Antibiotic TD-6424
Phase 2 Trials Underway For Serious Infections Caused by Gram-Positive Bacteria
Toggle Summary Theravance Announces Data on Novel Anesthesia Program
Theravance Announces Data on Novel Anesthesia Program SOUTH SAN FRANCISCO, Calif., November 24, 2003 /PRNewswire/ -- Theravance, Inc., today announced that results from a study with its investigational intravenous pharmacokinetically-responsive sedative hypnotic THRX-918661 were recently presented
Toggle Summary Theravance Announces Positive Phase 2 Results for Once-Daily Beta2-Agonists in Development for Asthma and COPD
Theravance Announces Positive Phase 2 Results for Once-Daily Beta2-Agonists in Development for Asthma and COPD SOUTH SAN FRANCISCO, CA December 3, 2003/ PR Newswire/ -- Theravance, Inc. announced today that the lead compounds in its alliance with GlaxoSmithKline (GSK) to identify new long-acting,
Presentations & Events
There are currently no events to display.

Copyright West LLC. Minimum 15 minutes delayed.

Contact

Toll-Free
877-202-1097

Innoviva Investor Relations & Media
Sloane and Company
212-446-9500

For business development inquiries,
please contact investor.relations@inva.com.